Antibody targeting ly6g6d and use thereof
A fully human anti-Ly6G6D antibody with optimized CDR sequences addresses immunogenicity and safety issues, enhancing the efficacy of antibody-based therapies for colorectal cancer.
AU2024411865A1Pending Publication Date: 2026-07-09SUNSHINE LAKE PHARMA CO LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- AU · AU
- Patent Type
- Applications
- Current Assignee / Owner
- SUNSHINE LAKE PHARMA CO LTD
- Filing Date
- 2024-11-25
- Publication Date
- 2026-07-09
AI Technical Summary
Technical Problem
Current antibody-based therapies targeting Ly6G6D for colorectal cancer suffer from immunogenicity and safety issues, limiting their efficacy.
Method used
Development of a fully human anti-Ly6G6D antibody with specific CDR sequences (SEQ ID NOs) that enhance affinity and reduce immunogenicity, providing a safer and more effective treatment option.
Benefits of technology
The new antibody exhibits superior efficacy and safety compared to rabbit- or mouse-derived antibodies, offering improved therapeutic potential for colorectal cancer treatment.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000000_0001_ABST 
Figure 00000000_0000_ABST
Abstract
Provided are an antibody targeting Ly6G6D and a use thereof. Specifically, provided are an anti-Ly6G6D (lymphocyte antigen 6 complex, locus G61) antibody and an antibody fragment. Further provided is a use of the antibody or antibody fragment in preparation of a drug for treating an Ly6G6D-positive cancer.
Need to check novelty before this filing date? Find Prior Art